Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262125 | 0.84 | TSHR (0.36) | ALDH1A1TSHR | |
| SCHEMBL15353486 | 0.75 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL4017 | 0.74 | — | — | |
| SCHEMBL260829 | 0.73 | ENPP3 (0.30) | — | |
| SCHEMBL1068722 | 0.73 | ENPP3 (0.30) | — | |
| SCHEMBL11504024 | 0.73 | CA2 (0.31) | — | |
| SCHEMBL6221220 | 0.73 | TSHR (0.37) | TSHR | |
| SCHEMBL1067884 | 0.73 | RAPGEF4 (0.31) | — | |
| SCHEMBL29049575 | 0.72 | — | — | |
| SCHEMBL20954103 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | GOLDFINCH BIO, INC. | 2024-03-21 | — | — | US | claimed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | claimed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | claimed |
| WO-2023192801-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| CN-111566109-B | 2,4,6, 7-tetrahydropyrazolo [4,3-d ] pyrimidin-5-one derivatives and related compounds for the treatment of vasculitis and inflammatory diseases | 爱杜西亚药品有限公司 | 2023-07-11 | — | — | CN | claimed |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | claimed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | claimed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | claimed |
| EP-0554167-A1 | Derivatives of 2,2-dimethyl-3-((2,2-difluorocyclopropylidene)-methyl)cyclopropanecarboxylic acid, process for their preparation and their use as pesticides | ROUSSEL-UCLAF (FR) | 1993-08-04 | — | — | EP | claimed |
| EP-0269573-B1 | LIQUID PHOTOINITIATING MIXTURE | CIBA-GEIGY AG (CH) | 1991-03-27 | — | — | EP | claimed |
| US-4960746-A | A-HYDROXY-OR A-AMINO-ACETOPHENONES AND A TITANOCENE COMPOUND SUBSTITUTED BY FLUORINE | CIBA-GEIGY CORPORATION (US) | 1990-10-02 | — | — | US | claimed |
| EP-0242330-B1 | LIQUID BLEND OF PHOTOINITIATORS | CIBA-GEIGY AG (CH) | 1990-05-16 | — | — | EP | claimed |
| EP-0269573-A2 | Liquid photoinitiating mixture | CIBA-GEIGY AG (CH) | 1988-06-01 | — | — | EP | claimed |
| EP-0242330-A1 | Liquid blend of photoinitiators | CIBA-GEIGY AG (CH) | 1987-10-21 | — | — | EP | claimed |
| US-4454149-A | Imidazo[1,2-a]imidazoles in the treatment of pain, hypertonia and coronary diseases | BOEHRINGER INGELHEIM KG (DE) | 1984-06-12 | — | — | US | claimed |
| US-4438118-A | ANALGESICS, CARDIOTONIC AGENTS, HYPOTENSIVE AGENTS | BOEHRINGER INGELHEIM KG (DE) | 1984-03-20 | — | — | US | claimed |
| EP-0007991-A1 | Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation | C.H. BOEHRINGER SOHN (DE) | 1980-02-20 | — | — | EP | claimed |
| US-4125620-A | HYPOTENSIVE | BOEHRINGER INGELHEIM GMBH (DE) | 1978-11-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ALDH1A1 2205/4885TSHR 4733/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | ALDH1A1 394/4885TSHR 1931/4885 |
| US-20240091303-A1 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | TRPC5, REN, SLC5A1 | ALDH1A1 3840/4885TSHR 4108/4885 |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | ALDH1A1 2010/4885TSHR 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.